Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product candidates address therapeutic areas with a high unmet medical need and strive to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. Its lead product candidate, EP-104IAR, is in development for the treatment of pain due to osteoarthritis of the knee. In addition, it is developing a pipeline of earlier-stage long-acting formulations.
| Last: | $8.16 |
|---|---|
| Change Percent: | 0.74% |
| Open: | $8.15 |
| Close: | $8.10 |
| High: | $8.2 |
| Low: | $8.11 |
| Volume: | 29,038 |
| Last Trade Date Time: | 02/27/2026 12:40:52 pm |
| Market Cap: | $435,556,805 |
|---|---|
| Float: | 34,844,532 |
| Insiders Ownership: | 4.18% |
| Institutions: | 8 |
| Short Percent: | N/A |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://www.eupraxiapharma.com |
| Country: | CA |
| City: | Victoria |
Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI FAQ is based on asking OpenAI questions about Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX).
Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.
Get instant news alerts to your mobile device as soon as the news hits the wire. Simply add a stock symbol to your portfolio and our service will alert you anytime there is news.
